Dana J H Niehaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2249042/publications.pdf

Version: 2024-02-01

			126907	1	133252	
	96	3,722 citations	33		59	
	papers	citations	h-index		g-index	
Ī						
	98	98	98		4121	
	90	90	90		4121	
	all docs	docs citations	times ranked		citing authors	

#	Article	IF	Citations
1	Ethnicity and Treatment Response in Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 9-14.	2.2	305
2	Quality of Life in Anxiety Disorders: A Comparison of Obsessive-Compulsive Disorder, Social Anxiety Disorder, and Panic Disorder. Psychopathology, 2003, 36, 255-262.	1.5	179
3	Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression and Anxiety, 2000, 11, 185-186.	4.1	170
4	Childhood trauma in obsessive-compulsive disorder, trichotillomania, and controls. Depression and Anxiety, 2002, 15, 66-68.	4.1	163
5	Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Comprehensive Psychiatry, 2001, 42, 291-300.	3.1	118
6	Trichotillomania and skin-picking: A phenomenological comparison. Depression and Anxiety, 2002, 15, 83-86.	4.1	117
7	Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the \hat{l}_{\pm} -galactosidase A gene. Human Molecular Genetics, 1994, 3, 1795-1799.	2.9	112
8	Gender in obsessive–compulsive disorder: clinical and genetic findings. European Neuropsychopharmacology, 2004, 14, 105-113.	0.7	111
9	Hoarding in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2005, 66, 1155-1160.	2.2	110
10	Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Comprehensive Psychiatry, 2005, 46, 14-19.	3.1	105
11	Early- versus late-onset obsessive–compulsive disorder: investigating genetic and clinical correlates. Psychiatry Research, 2004, 128, 175-182.	3.3	99
12	Obsessive-compulsive disorder and trichotillomania: a phenomenological comparison. BMC Psychiatry, 2005, 5, 2.	2.6	91
13	Remission in First-Episode Psychosis. Journal of Clinical Psychiatry, 2006, 67, 1707-1712.	2.2	88
14	Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology, 2008, 28, 210-213.	1.4	87
15	Dissociative experiences in obsessive-compulsive disorder and trichotillomania: Clinical and genetic findings. Comprehensive Psychiatry, 2004, 45, 384-391.	3.1	84
16	Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology, 2008, 23, 325-331.	1.7	84
17	The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophrenia Research, 2006, 84, 112-120.	2.0	83
18	Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. European Neuropsychopharmacology, 2003, 13, 93-98.	0.7	82

#	Article	lF	CITATIONS
19	Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies. Clinical Therapeutics, 2008, 30, 2378-2386.	2.5	71
20	Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 80-83.	1.4	62
21	Symptom Recurrence Following Intermittent Treatment in First-Episode Schizophrenia Successfully Treated for 2 Years. Journal of Clinical Psychiatry, 2012, 73, e541-e547.	2.2	60
22	Perceptions of a South African schizophrenia population with regards to community attitudes towards their illness. Social Psychiatry and Psychiatric Epidemiology, 2006, 41, 619-623.	3.1	58
23	Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country. Acta Psychiatrica Scandinavica, 2005, 111, 214-219.	4.5	54
24	Topiramate in the treatment of trichotillomania: an open-label pilot study. International Clinical Psychopharmacology, 2006, 21, 255-259.	1.7	54
25	Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia patients: Evidence for a neurocognitive endophenotype. Schizophrenia Research, 2008, 99, 270-273.	2.0	53
26	Elucidation of <i>CYP2D6</i> Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. Annals of Human Genetics, 2010, 74, 340-350.	0.8	53
27	Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial. Psychiatry Research, 2008, 161, 284-291.	3.3	51
28	Association between a catechol-o-methyltransferase polymorphism and obsessive–compulsive disorder in the Afrikaner population. Journal of Affective Disorders, 2001, 65, 61-65.	4.1	47
29	Genetic Variability in <i>CHMP2B</i> and Frontotemporal Dementia. Neurodegenerative Diseases, 2006, 3, 129-133.	1.4	47
30	Characterization of the genetic profile of <i>CYP2C19</i> in two South African populations. Pharmacogenomics, 2010, 11, 1095-1103.	1.3	46
31	Obsessive–compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population. International Journal of Neuropsychopharmacology, 2000, 3, 327-331.	2.1	44
32	The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia. Schizophrenia Research, 2001, 47, 149-157.	2.0	42
33	Maternal perinatal mental health and infant and toddler neurodevelopment - Evidence from low and middle-income countries. A systematic review. Journal of Affective Disorders, 2020, 268, 158-172.	4.1	38
34	A Culture-Bound Syndrome â€~Amafufunyana' and a Culture-Specific Event â€~Ukuthwasa': Differentiated a Family History of Schizophrenia and other Psychiatric Disorders. Psychopathology, 2004, 37, 59-63.	l by 1:5	37
35	Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. International Clinical Psychopharmacology, 2008, 23, 43-48.	1.7	36
36	Emotional face processing deficit in schizophrenia: A replication study in a South African Xhosa population. Schizophrenia Research, 2006, 84, 323-330.	2.0	35

#	Article	IF	Citations
37	Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 664-672.	4.8	35
38	Association study in three different populations between the <scp>GPR</scp> 88 gene and major psychoses. Molecular Genetics & amp; Genomic Medicine, 2014, 2, 152-159.	1.2	33
39	Next-generation sequencing of pharmacogenes. Pharmacogenetics and Genomics, 2013, 23, 666-674.	1.5	32
40	Stereotypies: Prevalence and Association with Compulsive and Impulsive Symptoms in College Students. Psychopathology, 2000, 33, 31-35.	1.5	31
41	Corrigendum to "Gender in obsessive–compulsive disorder: clinical and genetic findings―[Eur. Neuropsychopharmacol. 14/2 (2004) 105–113]. European Neuropsychopharmacology, 2004, 14, 437-445.	0.7	31
42	Crisis discharges and readmission risk in acute psychiatric male inpatients. BMC Psychiatry, 2008, 8, 44.	2.6	28
43	Characterization of the genetic variation present in CYP3A4 in three South African populations. Frontiers in Genetics, 2013, 4, 17.	2.3	28
44	Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 449-457.	1.4	27
45	Positive and negative symptoms in affected sib pairs with schizophrenia: Implications for genetic studies in an African Xhosa sample. Schizophrenia Research, 2005, 79, 239-249.	2.0	25
46	The relationships between depression and remission in first-episode psychosis. World Psychiatry, 2006, 5, 172-6.	10.4	25
47	Subjective awareness of tardive dyskinesia and insight in schizophrenia. European Psychiatry, 2011, 26, 293-296.	0.2	24
48	Negative Symptoms and HIV/AIDS Risk-Behavior Knowledge in Schizophrenia. Psychosomatics, 2007, 48, 128-134.	2.5	21
49	Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics, 2011, 12, 1717-1728.	1.3	21
50	Burnout and job satisfaction of nursing staff in a South African acute mental health setting. South African Journal of Psychiatry, 2020, 26, 1454.	0.4	18
51	Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics, 2014, 15, 189-199.	1.3	17
52	The impact of a psychiatry clinical rotation on the attitude of South African final year medical students towards mental illness. BMC Medical Education, 2019, 19, 114.	2.4	17
53	Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 163-169.	4.8	15
54	The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. Pharmacogenetics and Genomics, 2016, 26, 235-242.	1.5	15

#	Article	IF	CITATIONS
55	Religious Delusions in a Xhosa Schizophrenia Population. Journal of Religion and Health, 2015, 54, 1555-1562.	1.7	13
56	Risk factors for unplanned pregnancy in women with mental illness living in a developing country. Archives of Women's Mental Health, 2018, 21, 323-331.	2.6	13
57	Phenomenology of Stereotypic Movement Disorder. Psychiatric Annals, 1998, 28, 307-312.	0.1	11
58	CAG repeat polymorphisms in KCNN3 (HSKCa3) and PPP2R2B show no association or linkage to schizophrenia., 2003, 116B, 45-50.		10
59	Initiation Rites as a Perceived Stressor for Isixhosa Males with Schizophrenia. Transcultural Psychiatry, 2007, 44, 292-299.	1.6	10
60	Obsessive compulsive disorder–prevalence in Xhosa-speaking schizophrenia patients. South African Medical Journal, 2005, 95, 120-2.	0.6	10
61	Can Bruxism Respond to Serotonin Reuptake Inhibitors?. Journal of Clinical Psychiatry, 1998, 59, 133.	2.2	9
62	Revisiting the African origins of attachment research—50 years on from Ainsworth: A descriptive review. Infant Mental Health Journal, 2019, 40, 799-816.	1.8	8
63	Stereotypic Movement Disorder. Journal of Clinical Psychiatry, 1997, 58, 177-178.	2.2	8
64	Season of Birth, Age and Negative Symptoms in a Xhosa Schizophrenia Sample from the Southern Hemisphere. Australian and New Zealand Journal of Psychiatry, 2006, 40, 698-703.	2.3	7
65	Cannabis use and abuse correlates in a homogenous South African schizophrenia population. South African Journal of Psychiatry, 2009, 15, 5.	0.4	7
66	Cross-cultural analysis of attention disengagement times supports the dissociation of faces and patterns in the infant brain. Scientific Reports, 2019, 9, 14414.	3.3	7
67	Predictors of Abnormal Involuntary Movement in an African Schizophrenia Population. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 317-326.	1.8	6
68	Undiagnosed metabolic syndrome and other adverse effects among clozapine users of Xhosa descent. South African Journal of Psychiatry, 2014, 20, 4.	0.4	6
69	Mothers' pupillary responses to infant facial expressions. Behavioral and Brain Functions, 2017, 13, 2.	3.3	6
70	An Attempt to Stem the Tide: Exploring the Effect of a 90-Day Transitional Care Intervention on Readmissions to an Acute Male Psychiatric Unit in South Africa. Archives of Psychiatric Nursing, 2018, 32, 384-389.	1.4	6
71	Shared Pleasure in early mother–infant interactions: a study in a high-risk South African sample. Early Child Development and Care, 2021, 191, 230-241.	1.3	6
72	Anxiety symptoms in schizophrenia: the need for heightened clinician awareness. Primary Care and Community Psychiatry, 2001, 7, 25-29.	0.4	6

#	Article	IF	CITATIONS
73	Morphological features in a Xhosa schizophrenia population. BMC Psychiatry, 2006, 6, 47.	2.6	4
74	Allocation of attention to the eye and mouth region of faces in schizophrenia patients. Cognitive Neuropsychiatry, 2008, 13, 505-519.	1.3	4
75	The Neurobiology of Trichotillomania. CNS Spectrums, 1998, 3, 47-51.	1.2	3
76	A Case of "Ifufunyane": A Xhosa Culture-Bound Syndrome. Journal of Psychiatric Practice, 2005, 11, 411-413.	0.7	3
77	A clinical profile of inpatient admissions to the psychogeriatric unit at Stikland Hospital. South African Journal of Psychiatry, 2019, 25, 1344.	0.4	3
78	Demographic and clinical profile of patients utilising a transitional care intervention in the Western Cape, South Africa. South African Journal of Psychiatry, 2020, 26, 1523.	0.4	3
79	Maternal Shared Pleasure, Infant Withdrawal, and Developmental Outcomes in a High Risk Setting in South Africa. Frontiers in Psychiatry, 2021, 12, 668009.	2.6	3
80	Chromosome 22q11 in a Xhosa schizophrenia population. South African Medical Journal, 2012, 102, 165.	0.6	3
81	Pupillary and Attentional Responses to Infant Facial Expressions in Mothers Across Socioeconomic Variations. Child Development, 2021, 92, e236-e251.	3.0	3
82	Facial affect recognition and exit examination performance in medical students: a prospective exploratory study. BMC Medical Education, 2014, 14, 245.	2.4	2
83	Associations Between Neonatal Cry Acoustics and Visual Attention During the First Year. Frontiers in Psychology, 2020, 11, 577510.	2.1	2
84	Perinatal suicidality: Risk factors in South African women with mental illness. South African Journal of Psychiatry, 0, 26, .	0.4	2
85	The Shared Pleasure Paradigm: A study in an observational birth cohort in South Africa. Archives of Women's Mental Health, 2022, 25, 227-235.	2.6	2
86	Early motor behavior of infants exposed to maternal mental health disorders â€" A South African perspective. Early Human Development, 2022, 168, 105572.	1.8	2
87	London Measure of Unplanned Pregnancy for South African women with mental illness: Exploring perspectives on pregnancy. South African Journal of Psychiatry, 2018, 24, .	0.4	1
88	The development of the visual screening tool for anxiety disorders and depression: Addressing barriers to screening for depression and anxiety disorders in hypertension and/or diabetes. African Journal of Primary Health Care and Family Medicine, 2018, 10, e1-e6.	0.8	1
89	Digit ratio as an endophenotype in a schizophrenia population. South African Journal of Psychiatry, 2021, 27, 1587.	0.4	1
90	Season of birth, age and negative symptoms in a Xhosa schizophrenia sample from the Southern Hemisphere. Australian and New Zealand Journal of Psychiatry, 2006, 40, 698-703.	2.3	1

#	Article	lF	CITATIONS
91	Do South African Xhosa-Speaking People with Schizophrenia Really Fare Better?. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 2020, 33, 31-41.	0.5	1
92	Occupation and schizophrenia in a Xhosa population-a variant of the social drift theory?. South African Medical Journal, 2004, 94, 42.	0.6	1
93	Pregnancy outcomes, early separation, and psychiatric relapse experienced by South African women with peripartum psychosis: a descriptive exploration. African Journal of Reproductive Health, 2020, 24, 58-68.	1.1	1
94	Descriptive outcomes for a cohort of high-frequency psychiatric service users in the Western Cape, South Africa after 10 years. South African Journal of Psychiatry, 0, 28, .	0.4	1
95	Emotion Recognition Deficits as a Neurocognitive Marker of Schizophrenia Liability., 2009, , 163-176.		O
96	Prioritising maternal mental health and infant neurodevelopment research in Africa – A call for action amidst the backdrop of the COVID‑19 pandemic. South African Journal of Psychiatry, 2022, 28, 1716.	0.4	0